A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
To demonstrate the acceptability and feasibility of recruitment to a randomised
chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or
Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate
cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Queen Mary University of London
Collaborators:
Barts and the London School of Medicine and Dentistry Cancer Research UK
Treatments:
Aspirin Cholecalciferol Ergocalciferols Vitamin D Vitamins